Kornimate/medical-research-clean huggingface dataset:
salivary and serum levels of chemerin and mmp-9 in oral premalignant and malignant lesions

Conditions: Precancerous Conditions; Oral Cancer

Summary: 45 individuals were subdivided into 3 groups, 15 patients with oral premalignant lesions, 15 patients with oral malignant lesions and 15 control individuals. levels of chemerin and mmp-9 were evaluated in serum and saliva of these subjects utilizing the elisa technique.

45 individuals were subdivided into 3 groups, 15 patients suffering from oral premalignant lesions, 15 patients suffering from oral malignant lesions and 15 individuals having age, gender and periodontal status matched with both patients groups acting as a control group. serum and whole unstimulated saliva samples were collected from all the included groups in order to determine chemerin and mmp-9 in serum and saliva utilizing the elisa technique.

Eligibility criteria:
inclusion criteria: * patients with oral premalignant lesions. * patients with oral malignant lesions. exclusion criteria: * any systemic disease other than oral premalignant or malignant lesions. smokers. pregnant females. periodontal diseases.
evaluation of feconomics for diagnosis of intestinal parasitic infections

Conditions: Intestinal Parasitic Infection

Summary: people of all ages are affected by intestinal parasitic infections(ipis) ; however, children are the most commonly affected, which is linked to their poor hygienic practices, and weak immune status. in children, ipis are associated with malabsorption, weight loss, anemia, poor growth rate, learning difficulties, mental retardation and intellectual problems . the difficulty of diagnosis is the main problem in the control of intestinal parasitic infections. the choice of a particular technique is usually influenced by affordability, simplicity, cost, sensitivity in addition to the level of technical skills involved. microscopic examination remains the cornerstone of parasitological diagnosis which is time consuming and requires an experienced observer to identify the organism. formalin-ether sedimentation technique is commonly used in laboratories owing to its ability to isolate a large variety of parasites. however, it's a labor intensive procedure and is usually associated with hazards of using the inflammable lipid solvents. the drawbacks of the previous techniques have encouraged the development of commercial products such as feconomics which is a new ready to use kit for concentration of stool samples in parasitological diagnosis. the aim of the study is : evaluation of the efficacy of feconomics technique in comparison to traditional techniques i.e., direct smear and formalin ethyl acetate sedimentation technique for the diagnosis of intestinal parasites in school children.


Eligibility criteria:
inclusion criteria: * school children whose age is between 6-12 years exclusion criteria: * children taking anti-parasitic drugs within the previous two weeks of stool sample collection .
understanding the sleep apnea/insomnia interaction

Conditions: Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders

Summary: nearly half of all patients with obstructive sleep apnea have insomnia symptoms, and in some, but not all cases, these insomnia symptoms are caused by the obstructive sleep apnea. the purpose of this study is to find out what type of insomnia symptoms are caused by obstructive sleep apnea and therefore most likely to respond to obstructive sleep apnea treatment with continuous positive airway pressure (also known as cpap) and if additional treatment with cognitive-behavioral therapy for insomnia is beneficial.


Eligibility criteria:
inclusion criteria: 1. sleep apnea 2. insomnia 3. age \>18 exclusion criteria: 1. sedative/psychoactive drug use recently 2. other clinically significant sleep disorders 3. previous treatment for obstructive sleep apnea (osa) 4. requires oxygen or bilevel pap therapy 5. clinically unstable medical condition 6. recent shift work 7. significant alcohol use 8. other clinically significant causes of insomnia 9. illicit drug use 10. prescription stimulants 11. safety restrictions 12. unable to treat sleep apnea with positive airway pressure therapy 13. communication barriers 14. cognitive impairment
prevalence of gastroesophageal reflux disease in peritoneal dialysis and hemodialysis patients

Conditions: Gastroesophageal Reflux Disease

Summary: the purpose of this study is to determine the prevalence of gerd among chronic kidney disease with peritoneal dialysis and hemodialysis in korea.

gastroesophageal reflux disease is a common upper gastrointestinal disorder in chronic kidney disease. but, little is known about the prevalence in dialysis patients. the aims of this study were to determine the prevalence of gerd among chronic kidney disease with peritoneal dialysis and hemodialysis in korea.

Eligibility criteria:
inclusion criteria: * peritoneal dialysis and hemodialysis patients exclusion criteria: * a history of abdominal surgery or with a proton pump inhibitor before 1 month and a eradication of h. pylori were excluded

Keywords: gastroesophageal reflux disease peritoneal dialysis hemodialysis
improving knowledge in heart failure inpatient with therapeutic education

Conditions: Heart Failure With Reduced Ejection Fraction; Heart Failure; With Decompensation; Pharmacist-Patient Relations; Medication Adherence; Knowledge, Attitudes, Practice

Summary: the objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. the knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. the intervention group will receive a therapeutic education intervention and usual hospital care and the control group will receive only usual hospital care.

heart failure patients are at risk of decompensation of their disease and frequent hospitalizations. poor adherence to their treatment may be the cause. by improving the knowledge of hospitalized heart failure patients about their disease and their medications, it is expected that these patients will adhere better to their heart failure drug therapy and benefit from a better effectiveness of their treatment. this could promote an improvement in their quality of life, a decrease in their risk of disease complications and even an increase in their life expectancy. the objective of this research project is to deploy a therapeutic teaching intervention at the bedside of decompensated and hospitalized heart failure patients, associated with follow-up by the pharmacist at discharge from the hospital, and to measure its impact on knowledge change (primary endpoint), on their beliefs about medications, on their therapeutic adherence, and on the consumption of unplanned care such as rehospitalizations and emergency room visits (secondary endpoints).

Eligibility criteria:
inclusion criteria: * hospitalization in the department of general internal medicine or cardiology for decompensated heart failure with lowered left ventricular ejection fraction (lvef) (≤40%) from any cause or mildly lowered lvef (41-49%) with the presence of heart failure-specific drug therapy * stability of the patient's clinical condition * ≥ 2 heart failure medications * ≥18 years * full capacity of discernment * absence of cognitive impairment * ability to speak, understand and read in french * get a personal telephone * consent form signed by the participant exclusion criteria: * inability to follow study procedures * institutionalized persons * asylum seekers, homeless people, prisoners * incapacity of judgment and discernment

Keywords: patient therapeutic education clinical pharmacy pharmaceutical care
postpartum uterotonic administration

Conditions: Postpartum Bleeding

Summary: the investigators are planning to determine the effect of the timing of oxytocin administration on the amount of blood loss, necessity for additional medical or surgical interventions.

the investigators are studying the effects of the timing of intramuscular oxytocin administration in the third stage of labour. the investigators are measuring the postpartum blood loss: quantitatively in the postpartum 1st hour and indirectly by the decrease in the hemoglobin-haematocrit levels in the postpartum 24th hour. the investigators are monitoring the length of the third stage of labour, and the need for extra uterotonics and/or surgical interventions.

Eligibility criteria:
inclusion criteria: * cephalic presentation * singleton pregnancy * gestational age \>35 weeks, * in active labour. * expected fetal birth weight 2500-4500 grams. exclusion criteria: * acute fetal distress * conversion to abdominal delivery * persistent high blood pressure (\>140/90mmhg) * placenta previa * ablatio placenta * previous c-section * uterine scar * postpartum hemorrhage in previous pregnancies. * hydramnios * maternal infection * forceps/vacuum assisted deliveries * abnormal placentation ( placenta accreta, increta or percreta) * coagulation defects * hemoglobin \< 8g/dl

Keywords: postpartum hemorrhage third stage of labour oxytocin uterotonics active management of third stage of labour
emergence of chemotherapy related hyperglycemia in non-diabetic patients

Conditions: Cancer; Colon Cancer; Breast Cancer; Malignant Lymphoma

Summary: to assess chemotherapy related hyperglycemia in non-diabetic patients, the investigators will assess the incidence of hyperglycemia and analyze co-medications and risk factors.


Eligibility criteria:
inclusion criteria: * patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, chop regimen) * patients without history of diabetes mellitus * normal glucose tolerance, as defined in the protocol exclusion criteria: * patients with diabetes mellitus or hyperglycemia, as defined in the protocol

Keywords: normoglycemia cancer chemotherapy hyperglycemia drug induced
staging of axillary lymph nodes using the pem flex solo ii pet scanner in patients with breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if pem scan can improve axillary lymph node staging by assessing if they are involved by cancer. your doctor may refer you for a pem scan, pem stands for positron emission mammography, a relatively new and advanced application of positron emission tomography or pet scanning. for decades, pet has helped doctors diagnose and treat disease.

subjects will receive bilateral (both sides) breast and axillary pem scans. all recruited subjects chosen for the study will have biopsy proven breast cancer and are eligible for chemotherapy. they will undergo bilateral breast mri for staging which is considered standard of care. breast mri and pem scans will be performed at at baseline (phase 0 or pre-operative phase), 2nd mri and pem after 1 to 2 weeks of nac (phase 1) and 3rd mri and pem after 1 to 2 weeks of phase 1 (phase 2). dce-mri and pem will be performed not more than 14 days apart within each phase. cranio-caudal (cc) and medial lateral oblique (mlo) pem views will be performed of both the ipsilateral and contralateral breast and axillae by a mammography technologist trained in mammographic positioning.

Eligibility criteria:
inclusion criteria: * women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e. lumpectomy). exclusion criteria: * children (\<18 years old) * pregnant or lactating women * diabetic patients (type i or ii) * patients who are scheduled for a sentinel node procedure using radioactive tc-99m within 24 hours of pem * patients who have not undergone a standard of care bilateral breast mri at uc.
study of cm313 (sc) injection in subjects with primary immune thrombocytopenia (itp)

Conditions: Primary Immune Thrombocytopenia

Summary: this is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of cm313 (sc) injection in patients with primary immune thrombocytopenia.


Eligibility criteria:
inclusion criteria: * 18 years old ≤ 75 years old, male or female. * fully understand and are able to comply with the requirements of the protocol and voluntarily sign the informed consent form. exclusion criteria: * previously received allogeneic stem cell transplantation or organ transplantation. * laboratory abnormalities with clinical significance at screening visit. * pregnant or breastfeeding women, or women planning to become pregnant or breastfeeding during the study period; male partners who plan to become pregnant during the study period. * with any other situations that are not suitable for participation in this study by the investigator.
calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits

Conditions: Stress Fracture

Summary: we conducted a double-blind, placebo-controlled randomized clinical trial of calcium and vitamin d supplementation in 5201 female naval recruits. during 8 weeks of basic training, supplementation with 2000 mg calcium and 800 iu vitamin d/day decreased incidence of stress fracture by 25%. the hypothesis was: supplementation with calcium 2000 mg/d and vitamin d 800 iu/d will significantly reduce the incidence of stress fractures in female navy recruits during 8 weeks of basic training.

introduction: stress fractures (sfx) are one of the most common and debilitating overuse injuries seen in military recruits, and they are also problematic for non-military athletic populations. the goal of this randomized double-blind, placebo-controlled study was to determine if a calcium and vitamin d intervention could reduce the incidence of sfx in female recruits during basic training. methods: we recruited 5201 female navy recruit volunteers and randomized them to a 2000 mg calcium and 800 iu vitamin d supplement/day or placebo. sfx were ascertained when recruits reported to the great lakes clinic with symptoms. all sfx were confirmed with radiography or technetium scan according to the usual navy protocol. results: a total of 309 subjects were diagnosed with a sfx resulting in an incidence of 5.9% per eight weeks. using "intention-to-treat" analysis by including all enrolled subjects, fisher's exact test found that the calcium and vitamin d group had a 25% lower incidence of sfx than the control group (6.6% vs 5.3%, respectively, p=0.03). the per protocol analysis, including only the 3700 recruits who completed the study, found a 27% lower incidence of fractures in the supplemented vs the control group (8.6% vs 6.8%, respectively, p=0.02). conclusions: generalizing the findings to the population of 14,416 females who entered basic training at the great lakes during the 24 months of recruitment, calcium and vitamin d supplementation for the entire cohort would have prevented about 130 persons per year from fracturing. such a decrease in sfx would be associated with a significant decrease in morbidity and financial costs.

Eligibility criteria:
inclusion criteria: * female entering basic recruit training at the great lakes naval station

Keywords: physical training military training bone fracture prevention young adult
artificial intelligence vs endoscopist identification in eus normal anatomy

Conditions: Gastrointestinal Diseases

Summary: endoscopic ultrasound (eus) visual impression is operator-dependant and can hinder diagnostic accuracy, especially in less experienced endoscopists. the implementation of artificial intelligence can potentially mitigate operator dependency and interpretation variability, helping or improving the overall accuracy. the investigators therefore aim to compare diagnostic accuracy between artificial intelligence (ai)-based model and the endoscopists when identifying normal anatomical structures in eus-procedures.

eus is an operator dependent procedure where accuracy depends on experience and skills. nowadays, eus-training can be achieved by a formal fellowship training in a center for 6-24 months or an informal training through didactic sessions with a short hands-on experience. however, parameters for a correct and complete learning experience measurement are yet to be defined. the implementation of artificial intelligence on eus can potentially mitigate the operator-dependent variable and improve diagnostic accuracy. therefore, detection of normal anatomical structures on a separate basis using an ai-based model, expert and non-expert endoscopists to determine where the ai would be most helpful. the investigators aim to compare the diagnostic accuracy of the ai-based model with the endoscopists identification of normal anatomical structures in eus procedures.

Eligibility criteria:
inclusion criteria: * expert gastrointestinal eus-endoscopists. * non-expert gastrointestinal endoscopists training for eus. * patients with chronic dyspepsia without other findings. * patients with previous ct images or upper digestive endoscopy reporting no other findings. * patients requiring eus for surveillance due to family history of pancreatic cancer without findings on mri. exclusion criteria: * internet connection less than 100 mbs per second. * patients with abnormal structures or with visible lesions.

Keywords: eus ai gastrointestinal
high strong ion difference fluid vs hartmann's solution on acid-base status in sepsis

Conditions: Septicemic Shock

Summary: this is a research to study primarily the effect of rapidly infused high strong ion difference (sid) fluid vs hartmann's solution in altering the ph and bicarbonate level of the patient, who is in sepsis with metabolic acidosis. half of the study population gets high sid fluid, while the other half will get hartmann's solution.

balanced fluids are preferred in initial resuscitation of septic patients based on several recent studies. the stewart's concept on acid-base balance predicts that high strong ion difference (sid) fluid thus will increase the ph level. high sid fluid are specially formulated by adding sodium bicarbonate into half saline solution, the resultant fluid contains sodium= 145mmol/l and chloride=70mmol/l (sid= 75) as compared to hartmann's solution with the sid of 20.

Eligibility criteria:
inclusion criteria: * age≥18 years * fulfills 2/3 qsofa criteria * presumed infection * a blood ph at presentation ≤ 7.35 * hyperlactatemia (blood lactate level, \>2mmol/l ) exclusion criteria: * existing cardiac failure, major cardiac arrhythmia, advanced chronic kidney disease or end stage failure * known pregnancy * suspected dengue * primary diagnosis is related to burn, trauma, or drug overdose * if more than 500cc of resuscitation fluid was administered before enrollment.
a study to explore the effect of sepranolone in tourette syndrome

Conditions: Tourette Syndrome; Tourette Syndrome in Adolescence

Summary: the study was an open-label, randomized, multicenter, parallel, phase 2a study in adolescents and adult patients with tourette syndrome that aimed to explore the efficacy of sepranolone as a treatment for tourette syndrome, by reducing the severity and frequency of tics. the total study duration from the screening visit to the final follow-up visit was approximately 26 weeks and included the following periods: * a baseline period of 4 weeks between the screening visit (visit 1) and randomization (4 weeks of baseline period were not needed in well-known adult subjects with stable tourette syndrome history over the past at least 4 weeks). a school holiday/annual leave period of 2-6 weeks where no study-related activities were done. * a randomized treatment period of 12 weeks * a safety follow-up period of 4 weeks


Eligibility criteria:
inclusion criteria: * tic severity score ≥ 20 yale global tic severity scale (ygtss) total score at baseline * the patient may have obsessive-compulsive disease (ocd) as a comorbidity exclusion criteria: * patient has participated in a clinical study over the past 30 days * evidence or history of neurological disease that may interfere with the study * malignant disease * unstable or clinical significant medical condition that could pose a risk * hiv/ongoing hepatitis * clinical significant findings in vital signs * history of anaphylactic reactions

Keywords: tourette syndrome in adults
efficacy and safety of linzagolix for the treatment of endometriosis-associated pain.

Conditions: Endometriosis

Summary: the primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (abt: estradiol (e2) 1 mg / norethisterone acetate (neta) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (eap).

this is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose abt (e2 1 mg/neta 0.5 mg) versus placebo in the management of moderate to severe eap in 450 women. eligible subjects who have completed the 6-month treatment period may enter a separate extension study for 6 additional months of active treatment (no placebo control). subjects who do not continue in the extension study will enter a 6 month treatment-free follow-up phase.

Eligibility criteria:
inclusion criteria: the subject must have: * her most recent surgical and - if available - histological diagnosis of pelvic endometriosis up to 10 years before screening. * moderate to severe endometriosis-associated pain during the screening period. * regular menstrual cycles. * bmi ≥ 18 kg/m2 at the screening visit. - exclusion criteria: the subject will be excluded if she: * is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study. * is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of entry into the screening period. * has had a surgical history of any major abdominal surgery within 6 months or any interventional surgery for endometriosis performed within a period of 2 months before screening. * did not respond to prior treatment with gnrh agonists or gnrh antagonists for endometriosis. * has a history of, or known, osteoporosis or other metabolic bone disease. * has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic or other chronic therapy which would interfere with the assessment of endometriosis-associated pain.

Keywords: dysmenorrhea dyspareunia dyschezia non-menstrual pelvic pain